Skip to content

Study · Randomized controlled trial · 2021

4 results

A Metabolomic Signature of Glucagon Action in Healthy Individuals With Overweight/Obesity.

Vega RB, Whytock KL, Gassenhuber J, Goebel B, Tillner J, Agueusop I, Truax AD, Yu G, Carnero E, Kapoor N, Gardell S, Sparks LM, Smith SR

Journal of the Endocrine Society25 Jun 2021Cited by 21 (Europe PMC)

PMID34337278 (opens in a new tab)PMCIDPMC8317630 (opens in a new tab)DOI10.1210/jendso/bvab118 (opens in a new tab)PepBankPUB-34337278
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In healthy people with overweight or obesity, both glucagon doses significantly changed the plasma metabolome as soon as 4 hours after infusion.

    In plain wordsIn healthy people with overweight or obesity, both glucagon doses changed blood metabolites compared with placebo.

    Peptide
    Glucagon
    Outcome
    MixedPlasma metabolome
    Study

    n: not reported in source

    Comparator
    Placebo control
    Outcome group
    Metabolic pathways and metabolomics · Metabolic and weight
    Studied dose
    12.5 or 25 ng/kg/min · infusion · 72 hoursAs given in this study (human).

    Source sentences

    Summary
    Glucagon (GCG 12.5 and GCG 25) resulted in significant changes in the plasma metabolome as soon as 4 hours following infusion.
    2 context sentences
    Summary · context
    In this study (NCT03139305), we performed a continuous 72-hour glucagon infusion in healthy individuals with overweight/obesity.
    Summary · context
    Participants were randomized to receive glucagon 12.5 ng/kg/min (GCG 12.5), glucagon 25 ng/kg/min (GCG 25), or a placebo control.
  2. 02HumanRandomized controlled trialMechanism

    In healthy people with overweight or obesity, amino acid metabolism pathways were among those most affected during glucagon infusion.

    In plain wordsIn healthy people with overweight or obesity, glucagon affected amino acid metabolism pathways compared with placebo.

    Peptide
    Glucagon
    Outcome
    Direction not reportedAmino acid metabolism pathways
    Study

    n: not reported in source

    Comparator
    Placebo control
    Outcome group
    Amino Acid Metabolism · Metabolic and weight
    Studied dose
    12.5 or 25 ng/kg/min · infusion · 72 hoursAs given in this study (human).

    Source sentences

    Summary
    Pathways involved in amino acid metabolism were among the most affected.
    2 context sentences
    Summary · context
    In this study (NCT03139305), we performed a continuous 72-hour glucagon infusion in healthy individuals with overweight/obesity.
    Summary · context
    Participants were randomized to receive glucagon 12.5 ng/kg/min (GCG 12.5), glucagon 25 ng/kg/min (GCG 25), or a placebo control.
  3. 03HumanRandomized controlled trialMechanism

    In healthy people with overweight or obesity, glucagon infusion produced a rapid, sustained reduction in a broad panel of amino acids.

    In plain wordsIn healthy people with overweight or obesity, glucagon lowered blood amino acids compared with placebo.

    Peptide
    Glucagon
    Outcome
    DecreasePlasma amino acids
    Study

    n: not reported in source

    Comparator
    Placebo control
    Outcome group
    Amino Acid Metabolism · Metabolic and weight
    Studied dose
    12.5 or 25 ng/kg/min · infusion · 72 hoursAs given in this study (human).

    Source sentences

    Summary
    Rapid and sustained reduction of a broad panel of amino acids was observed.
    2 context sentences
    Summary · context
    In this study (NCT03139305), we performed a continuous 72-hour glucagon infusion in healthy individuals with overweight/obesity.
    Summary · context
    Participants were randomized to receive glucagon 12.5 ng/kg/min (GCG 12.5), glucagon 25 ng/kg/min (GCG 25), or a placebo control.
  4. 04HumanRandomized controlled trialMechanism

    In healthy people with overweight or obesity, glucagon infusion produced time-dependent changes in free fatty acids, diacylglycerol, and triglyceride species.

    In plain wordsIn healthy people with overweight or obesity, blood lipid species changed over time during glucagon infusion compared with placebo.

    Peptide
    Glucagon
    Outcome
    Direction not reportedCirculating lipid species
    Study

    n: not reported in source

    Comparator
    Placebo control
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    12.5 or 25 ng/kg/min · infusion · 72 hoursAs given in this study (human).

    Source sentences

    Summary
    Additionally, time-dependent changes in free fatty acids and diacylglycerol and triglyceride species were observed.
    2 context sentences
    Summary · context
    In this study (NCT03139305), we performed a continuous 72-hour glucagon infusion in healthy individuals with overweight/obesity.
    Summary · context
    Participants were randomized to receive glucagon 12.5 ng/kg/min (GCG 12.5), glucagon 25 ng/kg/min (GCG 25), or a placebo control.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.